Pharmacokinetic profiles and egg residue patterns of levamisole in laying hens at two dosing rates and two routes of administration

The levamisole maximum residue limit for edible fat, kidney, and muscle of chickens is 0.01 mg/kg. However, no maximum residue limit has been established for eggs. In the present study, the pharmacokinetic profile and levamisole residue in the eggs from laying hens were investigated using ultra -performance liquid chromatography-tandem mass spectrometry. A single dose of levamisole (30 mg/kg) was administered via the intramuscular or oral route, and an additional egg residue study was performed with 300 or 600 mg/kg commercial LEV drug (30 or 60 mg/kg as levamisole) orally. The limit of quantification was 0.0056 mg/mL and 0.0015 mg/kg for plasma and eggs, respectively. The plasma concentration was below the limit ofquantification 10 and 12 h after intramuscular and oral administration, respectively. The half-life of the absorption phase was comparable between the intramuscular and oral routes, which was approximately 1 h, and the mean maximum concentration value was significantly higher in intramuscular (2.29 +/- 0.30 mg/mL) than in oral (1.45 +/- 0.38 mg/mL) route. The relative oral bioavailability after intramuscular administration was 92.3%. In the egg residue study, dose-dependent area under concentration and maximum concentration were observed after single oral administration of 30 and 60 mg/kg egg residue, and the calculated withdrawal period for both 30 and 60 mg/kg groups based on the positive list system standard (0.01 mg/kg) was 7 d after the treatment.

Automated summary

This study investigated the pharmacokinetic profile and residue of levamisole in eggs. The results showed that the residue of levamisole in eggs is dose-dependent. According to the current standards, a withdrawal period of 7 days is needed after treatment to ensure that the residue of levamisole in eggs is below the limit.